India Pharma Outlook Team | Friday, 29 August 2025
Bristol Myers Squibb presented major clinical and real-world results of its cardiovascular line at the European Society of Cardiology (ESC) Congress, which took place between August 29 and September 1, 2025, in Madrid, Spain. New data on Camzyos (mavacamten) in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and data on Eliquis (apixaban) by the BMS-Pfizer Alliance were supported in the presentations.
“With a 70-year legacy in cardiovascular medicine, we are deeply committed to advancing life-changing therapies for patients, including those living with symptomatic obstructive HCM,” said Roland Chen, MD, senior vice president, drug development, immunology and cardiovascular medicines, Bristol Myers Squibb.
“Camzyos is the first and only available cardiac myosin inhibitor supported by robust long-term extension and real-world effectiveness data in patients with oHCM, with clinical studies demonstrating symptom relief as well as improvements in functional capacity and cardiac structure, both with and without background therapy. We look forward to sharing new data at this year’s ESC Congress building on our growing body of real-world evidence that reinforce its overall safety profile and benefits for diverse patients around the world,” said Roland.
The main presentations will feature real-world results of the COLLIGO-HCM study conducted in five countries, a collective analysis of four phase 3 trials that evaluate the effects of Camzyos monotherapy, and topline results of the largest phase 3 trial to date in the symptomatic non-obstructive HCM, ODYSSEY-HCM.
Also Read: How to Bridge the Healthcare Gap in Emerging Markets with MedTech
The initial cardiac myosin inhibitor to be approved in the US and more than 50 countries, Camzyos, enhances cardiac performance by balancing myosin-actin interactions, decreasing left ventricular outflow tract obstruction and increasing activity levels in patients. Eliquis is an oral Factor Xa inhibitor that remains a progressing drug in stroke prevention, deep vein thrombosis, pulmonary embolism, and venous thromboembolism in adult and pediatric patients.
Bristol Myers Squibb is still geared towards the innovative therapies that assist patients to overcome severe illnesses with the help of the bold science that is shaping the future of cardiovascular medicine.
